DigestRedComo funciona
Red
/
Empresas
Ro
No verificado

Rondo Therapeutics

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

6 Comunicados de prensa

Ver todos los comunicados de prensa
03/12/2025
Industria
Ciencia
Biotecnología
Farmacéutica
Oncología
Sanidad
Salud
Medicina - Varios
Rondo Therapeutics Doses First Patient in Phase 1 Trial of RNDO-564, a First-in-Class Co-Stimulatory Bispecific Antibody Targeting Nectin-4 in Advanced Solid Tumors
Fuente
Rondo Therapeutics
Editor
Business Wire
1.00
0
08/04/2025
Oncología
Salud
Ciencia
Farmacéutica
Biotecnología
Rondo Therapeutics Publishes Preclinical Data on RNDO-564, a Novel CD28 x Nectin-4 Co-Stimulatory Bispecific Antibody for the Treatment of Bladder Cancer
Fuente
Rondo Therapeutics
Editor
Business Wire
1.00
0
10/02/2025
Ciencia
Biotecnología
Farmacéutica
Oncología
Sanidad
Salud
Medicina - Varios
Eventos
Industria
Rondo Therapeutics Presents Preclinical Data at ASCO GU for its Novel CD28 x Nectin-4 Costimulatory Bispecific Antibody for Advanced Bladder Cancer
Fuente
Rondo Therapeutics
Editor
Business Wire
1.00
0
04/12/2024
Mercado laboral
Industria
Ciencia
Medicina - Varios
Biología
Biotecnología
Salud
Farmacéutica
Sanidad
Oncología
Rondo Therapeutics Announces Collaboration with Lilly to Develop Novel CD28 Bispecific Antibodies for Solid Tumors
Fuente
Rondo Therapeutics
Editor
Business Wire
1.00
0
19/11/2024
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Mercado laboral
Thomas Manley, M.D. Joins Rondo Therapeutics as Chief Medical Officer to Lead Clinical Development of Rondo Therapeutics’ Bispecific Antibody Programs
Fuente
Rondo Therapeutics
Editor
Business Wire
1.00
0
02/07/2024
Steven James, Accomplished CEO and Biotech Executive, Joins Board of Directors of Rondo Therapeutics
Fuente
Rondo Therapeutics
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0